2015 Fiscal Year Final Research Report
RAGE as a novel type 1 pneumocyte-derived biomarker and therapeutic target for IPF
| Project/Area Number |
25860645
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 間質性肺炎 / バイオマーカー / 肺胞上皮 |
|---|
| Outline of Final Research Achievements |
Seven tag polymorphisms of AGER were examined in 87 Japanese patients with idiopathic pulmonary fibrosis (IPF) and 303 healthy controls. The frequencies of AGER rs2070600 genotypes with minor allele (T) were significantly higher in the patients with IPF. Additionally, the carriage of rs2070600 minor allele (T) and the presence of IPF were independently associated with reduced serum levels of soluble receptor for advanced glycation end products (sRAGE), which were measured by ELISA. Serum sRAGE levels were significantly lower in IPF and in NSIP when compared with control subjects. Moreover, reduced sRAGE was related to the occurrence of acute exacerbation of IPF and was an independent predictor for the 5-year survival in the patients with IPF.
|
| Free Research Field |
呼吸器内科
|
